Imlifidase

Kidney transplantation in highly sensitized patients

Manufacturer: Hansa Biopharma
Regulatory submission: BLA submitted December 2025
Launch: Anticipated in the first quarter of 2027
Last updated: September 19, 2026

Section

Product information and disease description Place of product in therapy

Disease description

18 evidence topics · 18 sources

Definition and etiology3 evidence topics · 2 sources
Epidemiology1 evidence topic · 1 source
Natural history, survival, and mortality2 evidence topics · 4 sources
Pathophysiology1 evidence topic · 1 source
Diagnosis1 evidence topic · 3 sources
Clinical presentation - signs and symptoms2 evidence topics · 1 source
Long-term morbidity2 evidence topics · 2 sources
Burden of Kidney transplantation in highly sensitized patients6 evidence topics · 7 sources